

Callitas Health Inc

09:39 25 Apr 2019

Callitas Health wins notice of allowance from US Patent and Trademark Office in regards to patent for new cannabis 'candy'

Callitas Health Inc (CSE:LILY) (OTCQB:MPHMF) updated investors Thursday about good news received from the US Patent and Trademark Office in regards to its application for a new patent on a new oral "candy" that delivers tetrahydrocannabinol (THC) and cannabidiol (CBD) through oral absorption.

US regulators have delivered a notice of allowance, which means this patent is pending as the US Patent and Trademark Office determined that a patent can be granted from Callitas's patent application, which was filed back in November of 2018.

READ: Callitas Health banks on CannaStrips and OTC products while swinging for the fence with blockbuster drugs

"This recent Notice of Allowance positions Callitas as an even stronger innovator in the cannabis pharma delivery & consumer goods markets, protecting a new and very exciting technology," said James Thompson, CEO of Callitas, in a statement. "This patent Notice of Allowance, along with our other pending patent applications in our cannabis pharma delivery and consumer goods portfolio, combined with our newly developed and expanding partnerships in the cannabis space is expected to create significant value for our shareholders."

READ: Callitas Health strikes up partnership with Simply Wholeistic on CannaStrip technology, dietary supplements

This notice of allowance for the new technology is one of a group of patent-pending technologies the company acquired in October of 2018 from Dr. Ronald Thompson.

The company signed an agreement to obtain this portfolio of patents in exchange for a royalty on sales for sold products which cover various cannabis delivery technologies.

"Each new patent granted and licensed takes Callitas to the next level in the cannabis industry, showing the company's legitimacy and strength in creating and producing cannabinoid delivery products," said Callitas's chief medical cannabis Advisor Dr. Gregory Smith, in a statement.

Callitas is a well-diversified health and wellness company with a large portfolio. It is developing remedies across five silos: OTC sexual health & wellness, prescriptions for female sexual health, weight management, cannabis delivery technologies and orphan drugs.


Callitas shares were trading at US\$0.094 in over-the-counter trading on Thursday afternoon.

Contact Ellen Kelleher at ellen@proactiveinvestors.com

Price: 0.11

Market Cap: \$3.62 m

1 Year Share Price Graph



Share Information

Code: LILY

Listing: CSE

52 week	High	Low
	0.16	0.05

Sector: Pharma & Biotech

Website: www.callitas.com

Company Synopsis:

Founded on Midwest values, our Cincinnati-based company is people-focused, always looking for ways to benefit our customers, shareholders, and employees. Our company was built on strong work ethic, honesty, and a desire to help others. Our number one goal is helping people by bringing products to market that improve quality of life.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Callitas Health Inc named herein, including the promotion by the Company of Callitas Health Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).